» Articles » PMID: 35525881

Expanding the Database of Signal-Anchor-Release Domain Endolysins Through Metagenomics

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Endolysins are bacteriophage-derived lytic enzymes with antimicrobial activity. The action of endolysins against Gram-negative bacteria remains a challenge due to the physical protection of the outer membrane. However, recent research has demonstrated that signal-anchor-release (SAR) endolysins permeate the outer membrane of Gram-negative bacteria. This study investigates 2628 putative endolysin genes identified in 183,298 bacteriophage genomes. Previously, bioinformatic approaches resulted in a database of 66 SAR endolysins. This manuscript almost doubles the list with 53 additional SAR endolysin candidates. Forty-eight of the putative SAR endolysins described in this study contained one muramidase catalytic domain, and five included additional cell wall-binding domains at the C-terminus. For the moment, SAR domains are found in four protein families: glycoside hydrolase family 19 (GH19), glycoside hydrolase family 24 (GH24), glycoside hydrolase family 25 (GH25), and glycoside hydrolase family 108 (GH108). These SAR lysis are clustered in eight groups based on biochemical properties and domain presence/absence. Therefore, in this study, we expand the arsenal of endolysin candidates that might act against Gram-negative bacteria and develop a consult database for antimicrobial proteins derived from bacteriophages.

Citing Articles

Combined effect of SAR-endolysin LysKpV475 with polymyxin B and bacteriophage phSE-5.

Gontijo M, Pereira Teles M, Martins Correia H, Jorge G, Rodrigues Santos Goes I, Fasabi Flores A Microbiology (Reading). 2024; 170(5).

PMID: 38739436 PMC: 11170124. DOI: 10.1099/mic.0.001462.


Engineering strategies and challenges of endolysin as an antibacterial agent against Gram-negative bacteria.

Zheng T, Zhang C Microb Biotechnol. 2024; 17(4):e14465.

PMID: 38593316 PMC: 11003714. DOI: 10.1111/1751-7915.14465.


Metagenomic analysis of hot spring soil for mining a novel thermostable enzybiotic.

Pantiora P, Georgakis N, Premetis G, Labrou N Appl Microbiol Biotechnol. 2024; 108(1):163.

PMID: 38252132 PMC: 10803476. DOI: 10.1007/s00253-023-12979-2.


Comparative genomics and proteomics analysis of phages infecting multi-drug resistant Escherichia coli O177 isolated from cattle faeces.

Montso P, Kropinski A, Mokoena F, Pierneef R, Mlambo V, Ateba C Sci Rep. 2023; 13(1):21426.

PMID: 38052835 PMC: 10698182. DOI: 10.1038/s41598-023-48788-w.


Complete genome analysis of , a species inhibiting O157:H7.

Lopez M, Gontijo M, Cardoso R, Batalha L, Renon Eller M, Bazzolli D Front Cell Infect Microbiol. 2023; 13:1178248.

PMID: 37274318 PMC: 10236363. DOI: 10.3389/fcimb.2023.1178248.

References
1.
Chanishvili N . Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res. 2012; 83:3-40. DOI: 10.1016/B978-0-12-394438-2.00001-3. View

2.
Du Toit A . Microbiome: Getting organized early in life. Nat Rev Microbiol. 2017; 15(3):135. DOI: 10.1038/nrmicro.2017.10. View

3.
Chan B, Abedon S . Bacteriophages and their enzymes in biofilm control. Curr Pharm Des. 2014; 21(1):85-99. DOI: 10.2174/1381612820666140905112311. View

4.
Lin D, Koskella B, Lin H . Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017; 8(3):162-173. PMC: 5547374. DOI: 10.4292/wjgpt.v8.i3.162. View

5.
Esposito S, Pennoni G, Mencarini V, Palladino N, Peccini L, Principi N . Antimicrobial Treatment of in Patients With Cystic Fibrosis. Front Pharmacol. 2019; 10:849. PMC: 6692479. DOI: 10.3389/fphar.2019.00849. View